Guilford Street Laboratories

ML-driven mass spectrometry for biomarker panels.

scientists hands placing samples into a machine

Guilford Street Laboratories (GSL) is a UCL spinout company dedicated to helping clients achieve their research objectives. It launched in 2023.

Leveraging machine learning-driven mass spectrometry, the company delivers highly precise and sensitive biomarker panels, specialising in the analysis of protein, lipid, and metabolite markers.

The Guilford Street Labs journey so far:

2023: founded as a spinout
2026: ImmunoTADA™ test launched with the NHS for patients living with Fabry disease.

Team

Professor Kevin Mills

Chief Scientific Officer

Internationally recognised leader in translational biomarker science and rare disease diagnostics. Professor of Translational Medicine at UCL.

Dr Wendy Heywood

Executive Director

Over 15 years experience in developing basic research for clinical application, runs largest translational research centre in UK. Co-developer of HCM Predict and creator of ImmunoTADA platform.

Dr. Caitriona O'Rourke (Away from office)

Senior Business Manager

Dr O’Rourke joined us in 2018, having worked as a research associate within UCL on several diverse life science / pharmaceutical research projects covering the areas of tissue engineering, drug delivery, regenerative medicine, biomaterials and stem cell biology.

Caitriona holds a PhD in tissue engineering from the Open University and a MSc in neuropharmacology from the National University of Galway, Ireland.